Skip to main content
. 2013 Sep 12;8(9):e74345. doi: 10.1371/journal.pone.0074345

Figure 4. Correlation between baseline CD109+ CECs and PFS/OS in patients treated with bevacizumab+irinotecan or bevacizumab alone.

Figure 4

Patients treated with bevacizumab and irinotecan and showing baseline CD109+ CEC count > 41.1/ml (1st quartile) had increased PFS and OS (panels A); PFS was significantly increased also in patients belonging to IDA and baseline CD109+ CEC count over the 1st quartile (panels B).